Inhalvent

Ipratropium bromide, the active ingredient in Inhalvent, is an anticholinergic presented as an inhalation solution for inhalation use. It provides bronchodilation and is prescribed for patients with chronic obstructive pulmonary disease (COPD) and asthma to improve airway airflow. It is formulated for delivery via a metered‑dose inhaler, allowing rapid onset of action in the lower respiratory tract.

GNH USA supplies Inhalvent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Ipratropium bromide is a bronchodilator anticholinergic used to manage airway obstruction in chronic respiratory diseases.

- Chronic Obstructive Pulmonary Disease (COPD): reduces airway resistance and improves breathing in patients with stable disease. - Asthma: provides additional bronchodilation as an adjunct therapy for patients whose symptoms are not fully controlled by other agents. - Acute Bronchospasm: offers rapid relief of bronchoconstriction during episodic airway narrowing.

Adverse reactions may occur with inhaled ipratropium bromide.

Common Side Effects: - Dry mouth: reduced salivary secretion leading to oral dryness. - Cough: irritation of the airway causing a transient cough. - Throat irritation: mild soreness or discomfort in the throat. - Headache: mild to moderate headache episodes. - Dizziness: occasional light‑headed sensation. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of airway narrowing. - Allergic reactions: rash, itching, or urticaria. - Angioedema: swelling of lips, tongue, or face. - Severe cough: persistent, debilitating cough. - Urinary retention: difficulty emptying the bladder, especially in predisposed individuals.

Before prescribing Inhalvent, clinicians should consider several safety aspects.

- Renal function assessment: ipratropium is excreted renally, dose adjustment may be needed in impairment. - Anticholinergic burden: monitor for additive dry‑mouth, constipation, or blurred vision when used with other anticholinergics. - Narrow‑angle glaucoma: use cautiously as it may increase intra‑ocular pressure. - Hypersensitivity: avoid in patients with known allergy to ipratropium or formulation components. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Ipratropium bromide may interact with other medications, requiring attention to the level of risk.

Major Interactions (Avoid): - Other anticholinergic inhalers: may amplify anticholinergic side effects such as dry mouth and urinary retention. - Beta‑2 agonists (high doses): additive bronchodilation can increase risk of tachycardia or tremor. - MAO inhibitors: potential for enhanced cholinergic imbalance.

Moderate Interactions (Monitor Closely):\n- Theophylline: ipratropium may increase serum theophylline concentrations; monitor levels. - Inhaled corticosteroids: combined use may raise infection risk; observe for respiratory infections. - Diuretics: monitor electrolyte balance, especially potassium, when used together.